Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + sozinibercept
- Development stage
- Unknown
- Lead developer
- Opthea
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Ranibizumab + sozinibercept is an investigational combination therapy for retinal vascular diseases, notably neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and polypoidal choroidal vasculopathy (PCV). Ranibizumab is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), while sozinibercept is a recombinant fusion protein that blocks VEGF-C and VEGF-D. By targeting multiple members of the VEGF family, this combination aims to provide more comprehensive inhibition of abnormal blood vessel growth and leakage in the retina. Clinical trials have shown that adding sozinibercept to ranibizumab improves visual acuity outcomes compared to ranibizumab alone, with additional anatomical benefits such as reduced retinal swelling and choroidal neovascularization area. The combination has demonstrated a favorable safety profile in studies to date[3][5][6][7][8].
- Brand names
- Lucentis
02
Targets
VEGFD (Vascular endothelial growth factor D)VEGFA (Vascular endothelial growth factor A)VEGFC (VEGF-C)
Beyond the preview
Go deeper on ranibizumab + sozinibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + sozinibercept.